Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethylamino)phenyl)cyclopentyl) methyl)urea hydrochloride and compositions, methods and kits related thereto

摘要

#$%^&*AU2020202784A120200514.pdf#####:1InterwovnNRPortblDCCSXD20129404_l.docx-27/04/2020 ABSTRACT A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to "ATR101") suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome. - 53-